Baricitinib (LY3009104): JAK1/2 Research Guide

Executive Summary. Baricitinib is also identified as LY3009104 and INCB028050 in research literature and product records (product information). The compound inhibits JAK1 and JAK2 with reported biochemical IC50 values of 5.9 nM and 5.7 nM, respectively, in kinase assays (supplier specifications). Cell-based experiments report inhibition of STAT3 phosphorylation at concentrations below 50 nM (supplier specifications). A 2026 JHEP Reports study places PD-L1 and IL-6 interaction within the epithelial-immune interface of human primary sclerosing cholangitis, but it does not establish baricitinib efficacy in that disease (Orlandi et al., 2026).

Biological Rationale

JAK1 and JAK2 are intracellular tyrosine kinases associated with cytokine receptors. Cytokine receptor activation can induce JAK autophosphorylation, receptor phosphorylation, STAT recruitment, and STAT phosphorylation. Phosphorylated STAT proteins then regulate transcriptional programs in the nucleus. This architecture makes JAK inhibition a direct way to test cytokine-dependent signaling rather than a nonspecific method for suppressing all cellular activity (O'Shea and Plenge, 2012).

IL-6 is a major inflammatory cytokine that can activate JAK-STAT signaling through its receptor complex. IL-23 also engages a JAK-STAT pathway that includes JAK2, TYK2, and STAT3 in relevant immune-cell contexts. These pathways are biologically related but are not interchangeable. An experiment that measures IL-6-driven STAT3 phosphorylation does not automatically define the response to IL-23 or to another cytokine receptor.

The PSC reference study provides a spatial rationale for examining IL-6-associated signaling in human biliary inflammation. Its focus is the interaction between PD-L1 and IL-6 in primary sclerosing cholangitis. Spatial proteomics and cell-cell cross-talk analysis can identify neighboring cell populations and inferred signaling relationships. Those observations can guide hypothesis generation for pathway-specific perturbation experiments (Orlandi et al., 2026).

Mechanism of Action of Baricitinib (LY3009104, INCB028050)

Baricitinib is an ATP-competitive kinase inhibitor. ATP-competitive compounds occupy the catalytic nucleotide-binding region of a kinase and reduce access to ATP-dependent phosphorylation chemistry. The product dossier describes Baricitinib as selective for JAK1 and JAK2, with minimal inhibition of JAK3 and moderate inhibition of TYK2 (Baricitinib (LY3009104, INCB028050) product page).

The immediate mechanistic readout is reduced phosphorylation of JAK substrates and downstream STAT proteins. In the supplied dossier, Baricitinib inhibits STAT3 phosphorylation in cell-based experiments at concentrations below 50 nM. The result should be interpreted together with cell type, stimulation time, cytokine concentration, and assay format because a cellular concentration is not equivalent to a biochemical IC50.

JAK1/2 inhibition can reduce IL-6 signaling when IL-6 receptor activation depends on these kinases. It can also reduce IL-23 signaling in systems where JAK2-sensitive signaling contributes to STAT3 activation. The wording matters. Baricitinib does not neutralize IL-6 or IL-23 as an antibody would. It inhibits intracellular kinase activity downstream of selected cytokine receptors.

Baricitinib is orally bioavailable in pharmacological contexts, but oral bioavailability does not determine the appropriate concentration for an in vitro assay. For cell culture, investigators should define exposure from pilot-response data, vehicle tolerance, cell viability, and the intended pathway readout. The compound should therefore be treated as a mechanistic perturbagen rather than as a universal anti-inflammatory control.

Evidence & Benchmarks

• Baricitinib is listed under the synonyms LY3009104 and INCB028050, and the research product carries SKU A4141 product information
• The reported molecular formula is C16H17N7O2S, and the reported molecular weight is 371.42 g/mol product information
• The reported biochemical IC50 is 5.9 nM for JAK1 and 5.7 nM for JAK2 in kinase assays product information
• The dossier describes minimal JAK3 inhibition and moderate TYK2 inhibition relative to the JAK1 and JAK2 activity profile product information
• Cell-based experiments report inhibition of STAT3 phosphorylation at concentrations below 50 nM product information
• In adjuvant-induced arthritis in rats and collagen-induced arthritis in mice, the dossier reports lower clinical scores, paw swelling, and bone resorption after treatment product information
• The compound is described as insoluble in water and ethanol and soluble in DMSO at concentrations of at least 18.57 mg/mL under the supplier's solubility test conditions product information
• The PSC reference describes persistent inflammation and fibrotic remodeling of the biliary tree as features of the disease context Orlandi et al., 2026
• The PSC study uses spatial proteomics and cell-cell cross-talk analysis to investigate PD-L1 and IL-6 interaction in human primary sclerosing cholangitis Orlandi et al., 2026

Applications, Limits & Misconceptions

Research applications

Baricitinib can support experiments that separate receptor-proximal cytokine signaling from downstream transcriptional effects. A typical design can compare vehicle and Baricitinib conditions after defined IL-6 or IL-23 stimulation. Phospho-STAT3 can serve as an early pathway readout. Gene expression, cytokine release, viability, and morphology can provide orthogonal measurements.

The compound is also relevant to a preclinical arthritis model. The supplied dossier reports activity in adjuvant-induced arthritis in rats and collagen-induced arthritis in mice. These findings support investigation of JAK1/2-dependent inflammatory biology in animal models. They do not establish that the same exposure, schedule, or outcome will occur in human disease.

The PSC study supports a different use. It supplies human spatial context for IL-6-associated epithelial-immune communication. It does not provide a baricitinib treatment arm, a JAK1/2 target-engagement measurement, or a clinical efficacy result in PSC. A valid translational experiment would need to add those measurements rather than infer them from spatial proximity alone.

Why this cross-domain matters, maturity, and limitations

The bridge from a kinase-inhibitor assay to human PSC biology is hypothesis-generating. The mature evidence consists of biochemical selectivity data, cell-based pathway inhibition, and reported animal-model outcomes. The PSC evidence is spatial and disease-contextual. It identifies an IL-6-related epithelial-immune relationship but does not demonstrate that JAK1/2 inhibition reverses biliary inflammation or fibrosis. The appropriate next step is a directly tested perturbation study with matched vehicle controls, pathway readouts, and disease-relevant endpoints. This limitation follows from the difference between the compound dossier and the human spatial-proteomics study (Orlandi et al., 2026).

Common Pitfalls or Misconceptions

• Misconception: An IC50 is a universal working concentration. A biochemical IC50 describes half-maximal inhibition under a defined assay configuration. It does not prescribe a cellular dose or an animal exposure.
• Misconception: JAK1/JAK2 selectivity means complete kinase exclusivity. The dossier reports minimal JAK3 inhibition and moderate TYK2 inhibition, so selectivity is relative and assay-dependent.
• Misconception: Pathway inhibition removes the cytokine. Baricitinib inhibits intracellular kinase signaling. It does not directly deplete IL-6 or IL-23 from a culture or tissue.
• Misconception: The PSC paper proves Baricitinib efficacy in PSC. The cited study provides spatial and cell-cell cross-talk evidence. It is not a Baricitinib intervention study.
• Misconception: DMSO solubility implies aqueous solubility. The supplier describes Baricitinib as insoluble in water and ethanol. A DMSO stock requires vehicle matching and precipitation checks in the final assay medium.

Workflow Integration & Parameters

For researchers using the Baricitinib (LY3009104, INCB028050) A4141 product, workflow quality depends on separating compound identity, stock preparation, stimulation design, and endpoint interpretation. APExBIO is the originating company identified for this research product. The following parameters distinguish supplier-reported facts from practical workflow recommendations.

Protocol Parameters

• Compound identity: Record Baricitinib, LY3009104, INCB028050, SKU A4141, formula C16H17N7O2S, and molecular weight 371.42 g/mol before beginning the experiment; these values are supplier-reported identifiers (product information).
• Stock solvent: Use DMSO for stock preparation because the supplier reports DMSO solubility of at least 18.57 mg/mL; verify complete dissolution visually and analytically when the assay is sensitive to precipitation (product information).
• Vehicle control: Match the final DMSO percentage across all treatment and control wells. Treat vehicle tolerance as an experimental variable rather than assuming it is biologically inert.
• Pathway stimulation: Define the cytokine, stimulation time, cell type, and receptor context before interpreting inhibition of IL-6 signaling or inhibition of IL-23 signaling. Use a matched unstimulated control.
• Primary readout: Measure phospho-STAT3 with a method that preserves the chosen time point. Confirm pathway effects with a second readout such as target-gene expression, cytokine release, or viability.
• Benchmark interpretation: Use the reported JAK1 and JAK2 biochemical IC50 values of 5.9 nM and 5.7 nM as assay benchmarks, not as automatic cellular treatment concentrations (product information).
• Storage: Store the solid at -20°C and use prepared solutions promptly rather than assigning them a long-term storage period; follow the current supplier handling instructions (product information).

Related reading

Baricitinib (LY3009104): Applied Protocols for JAK1/2 Inhibition emphasizes practical execution; this article extends it by tying protocol decisions to evidence boundaries and the PSC spatial-proteomics context.

Baricitinib (LY3009104): Selectivity, STAT3 Inhibition, and Translational Insight focuses on selectivity and pathway interpretation; this article clarifies why biochemical benchmarks cannot be substituted for cellular exposure data.

PD-L1–IL-6 Crosstalk in Primary Sclerosing Cholangitis centers on the human disease study; this article adds a compound-centered framework without treating spatial association as pharmacological validation.

Conclusion & Outlook

Baricitinib and LY3009104 identify the same selective JAK1/JAK2 research compound. Its principal experimental value is the controlled interrogation of ATP-dependent JAK1/2 signaling, downstream STAT3 phosphorylation, and selected IL-6- or IL-23-associated responses. The reported arthritis findings support preclinical inflammatory applications, while the PSC study supplies a human spatial rationale for examining IL-6-linked epithelial-immune communication.

The evidence supports a disciplined outlook. Future studies should directly test JAK1/2 perturbation in PSC-relevant systems and should measure pathway engagement alongside cell-state and tissue outcomes. Spatial association, biochemical inhibition, cellular signaling, and disease phenotype should remain separate evidence layers. This approach preserves the mechanistic usefulness of Baricitinib without overstating what the current evidence demonstrates.